In February, the Cancer Treatment Centers of America announced a collaborative alliance with NantHealth called Clinical Pathways. This unifying program will help erase trial and error research, by providing oncology professionals with up to date information and awareness of all progressive advances in cancer research.
This will help physicians and patients work together to coordinate safe and effective treatment options. Clinical pathways is focused on the patient aspect of cancer treatment as much as it is about connecting cancer researchers. It will seamlessly assimilate essential records automatically into the doctor’s electronic health record (EHR).
Cancer patients will now be able to rely on their physician’s decisions to implement treatment programs unique to their situation. It is a welcome change from the restrictive and impersonal one-size fits all approach. With cancer research evolving on a daily basis, it has become essential to arm oncologists with current information. Through the Clinical Pathways program they will have access to clinically supported data, response statistics and problems encountered with particular treatment drugs.
This news reinforces the Cancer Treatment Centers of America theory that no two patients are alike and no two cancers are alike. Since the first Cancer Treatment Center was opened in 1988, they have consistently endeavored to personalize every treatment plan.
They have been at the forefront of cancer research throughout their history, as the focus exclusively on nothing but cancer. Cancer Treatment Centers of America have evolved as cancer research and treatment have evolved. This new patient-focused program is another step towards beating cancer.
The battle against cancer is ongoing and a fight that affects the lives of thousands. Clinical Pathways is a coordinated effort to prioritize the patient’s needs and provide a more efficient method of treatment. It acknowledges that no two situations are alike and allows for individuality and consistency in the treatment of cancer.